8-K

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 3, 2004

AMEDISYS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction of

Incorporation or Organization)

0-24260	11-3131700
(Commission File Number)	(I.R.S. Employer Identification No.)

11100 Mead Road, Suite 300, Baton Rouge, LA 70816

(Address of principal executive offices including zip code)

(225) 292-2031

(Registrant’s telephone number, including area code)

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(a)	Financial Statements of Business Acquired.
	Not applicable.
(b)	Pro Forma Financial Information.
	Not applicable.
(c)	Exhibit No.
	99.1 (i)	Press Release dated August 3, 2004 announcing the Company’s second quarter 2004 operating results

(i) Filed herewith.

Item 12. Results of Operations and Financial Condition.

The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section. The information in this Current Report shall not be incorporated by reference into any registration statement or document pursuant to the Securities Act of 1933, as amended.

On August 3, 2004, Amedisys, Inc. issued a press release attached hereto as Exhibit 99.1 announcing its financial results for the second quarter of fiscal year 2004, which ended June 30, 2004.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDISYS, INC.
By:	/s/ Gregory H. Browne
	Gregory H. Browne
	Chief Financial Officer

DATE: August 3, 2004

EX-99.1

Exhibit 99.1

AMEDISYS REPORTS SECOND QUARTER 2004

RESULTS

Company Reports Record Quarterly Revenue and Provides Increased

Guidance for 2004

AMEDISYS TO HOST CONFERENCE CALL

TODAY AT 10:00 AM ET

BATON ROUGE, Louisiana (August 3, 2004) – Amedisys, Inc. (NasdaqNM: “AMED” or “the Company”), one of America’s leading home health nursing companies, today reported its financial results for the second quarter of 2004.

For the quarter ended June 30, 2004 the Company reported net income of $5.0 million, or $0.39 per diluted share, on record net service revenue of $56.9 million. Net service revenue increased by 77% when compared with the $32.2 million reported for the comparable period in the prior year. Amedisys reported net income of $1.5 million, or $0.16 per diluted share for the June quarter of 2003. The diluted weighted average number of shares outstanding approximated 12.8 million in the quarter ended June 30, 2004 and 9.7 million in the comparable period of 2003.

For the six months ended June 30, 2004 the Company reported net income of $9.2 million, or $0.72 per diluted share, on record net service revenue of $104.2 million. For the same period the previous year, Amedisys reported net income of $2.7 million, or $0.28 per diluted share, on net service revenue of $63.3 million. The diluted weighted average number of shares outstanding approximated 12.7 million in the six months ended June 30, 2004 and 9.6 million in the comparable period of 2003.

“Our ongoing commitment to both organic growth and selective acquisitions has resulted in the achievement of record revenue and strong year-over-year increase in net income,” noted William F. Borne, Chief Executive Officer of Amedisys. “Clearly, we are extremely pleased with the results, which exceeded guidance previously communicated, and we remain confident that Amedisys can continue to deliver strong earnings growth for our shareholders. Therefore, based on currently available information, we are increasing our earnings guidance for fiscal 2004 to between $1.43 and $1.49 cents per diluted share, on revenue which is expected to exceed $215 million.”

“Internal growth of Medicare patient admissions was approximately 34 percent in the second quarter when compared with the previous year, which is by far the strongest growth rate ever achieved by the Company,” continued Borne. “The substantial increase in the rate of growth experienced in 2004 can be attributed to the collective results of a number of strategic initiatives begun in 2002, including, the single-minded focus of a more experienced and better trained sales force, making available an

expanded range of clinical programs, and an increased effort aimed at educating referral sources on the benefits of home health nursing. Further, we have continued to initiate new locations through start ups, and expect this strategy to accelerate into 2005.”

“The integration of the operations acquired from Tenet Healthcare Corporation has now been substantially completed, although significant effort will be required to ensure that these locations contribute to the Company’s overall financial results. We are also pleased with the progress made to date by our most recent acquisition in Vicksburg, Mississippi.”

The Company will provide further information today on these results during a teleconference call that is scheduled for 10:00 a.m. ET. To access this call, please dial 1-800-231-5571 (domestic) or 1-973-582-2703 (international). A replay of the conference call will be available until August 10th, 2004, by dialing 1-877-519-4471 (domestic) or 1-973-341-3080 (international). The replay pin number is 4982538.

Amedisys, Inc., a leading provider of home health nursing services, is headquartered in Baton Rouge, Louisiana. Its common stock trades on The Nasdaq Stock Market under the symbol “AMED”.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s services in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company’s periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Additional information on the Company can be found on the World Wide Web

http://www.amedisys.com

Contact:	Amedisys, Inc.
	Gregory H. Browne, CFO
	(225) 292-2031
	gbrowne@amedisys.com
	Investor Relations: Euro RSCG Life NRP
	Brian Ritchie (212) 845-4269
	brian.ritchie@eurorscg.com

2

AMEDISYS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

For the three and six months ended June 30, 2004 and 2003

(Amounts in thousands, except per share data)

	(Unaudited)
	For the three months ended June 30						For the six months ended June 30
	2004			2003			2004			2003
Income:
Net service revenue	$	56,896		$	32,194		$	104,235		$	63,326
Cost of service revenue (excluding depreciation and amortization)		23,613			13,100			43,093			26,009
Gross margin		33,283			19,094			61,142			37,317
General and administrative expenses:
Salaries and benefits		14,794			9,881			27,351			19,742
Other		10,406			6,657			18,803			12,835
Total general and administrative expenses		25,200			16,538			46,154			32,577
Operating income		8,083			2,556			14,988			4,740
Other income (expense):
Interest income		44			24			96			41
Interest expense		(100	)		(341	)		(224	)		(701	)
Miscellaneous		(3	)		199			(7	)		209
Total other expense, net		(59	)		(118	)		(135	)		(451	)
Income before income taxes		8,024			2,438			14,853			4,289
Income tax expense		3,063			924			5,671			1,626
Net income	$	4,961		$	1,514		$	9,182		$	2,663
Basic weighted average common shares outstanding		12,281			9,477			12,144			9,402
Basic income per common share:
Net income	$	0.40		$	0.16		$	0.76		$	0.28
Diluted weighted average common shares outstanding		12,804			9,666			12,683			9,583
Diluted income per common share:
Net income	$	0.39		$	0.16		$	0.72		$	0.28

3

AMEDISYS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

As of June 30, 2004 and December 31, 2003

(Amounts in thousands, except share data)

	June 30, 2004			December 31, 2003
	(unaudited)
ASSETS:
CURRENT ASSETS:
Cash and cash equivalents	$	22,279		$	29,779
Patient accounts receivable, net of allowance for doubtful accounts of $3,624 at June 30, 2004 and $3,008 at December 31, 2003		19,841			15,185
Prepaid expenses		2,268			1,103
Deferred income taxes		—			1,650
Inventory and other current assets		1,123			1,879
Total current assets		45,511			49,596
Property and equipment, net		8,121			7,219
Goodwill and other assets, net		57,383			35,658
Total assets	$	111,015		$	92,473
LIABILITIES AND STOCKHOLDERS’ EQUITY:
CURRENT LIABILITIES:
Accounts payable	$	3,255		$	3,340
Accrued expenses:
Payroll and payroll taxes		13,536			9,163
Insurance		2,908			2,336
Income taxes		1,400			575
Legal settlements		1,367			1,248
Other		3,919			2,818
Deferred income taxes		532			—
Current portion of long-term debt		3,875			3,974
Current portion of obligations under capital leases		456			1,217
Current portion of Medicare liabilities		9,326			9,347
Total current liabilities		40,574			34,018
Long-term debt		921			2,696
Obligations under capital leases		486			391
Deferred income taxes		3,725			2,756
Other long-term liabilities		1,213			1,213
Total liabilities		46,919			41,074
STOCKHOLDERS’ EQUITY:
Preferred stock, $.001 par value, 5,000,000 shares authorized; None issued and outstanding		—			—
Common stock, $.001 par value, 30,000,000 shares authorized; and 12,359,648 and 11,908,146 shares issued at June 30, 2004 and December 31, 2003, respectively		12			12
Additional paid-in capital		58,980			55,465
Treasury stock at cost, 4,167 shares held		(25	)		(25	)
Retained earnings (deficit)		5,129			(4,053	)
Total stockholders’ equity		64,096			51,399
Total liabilities and stockholders’ equity	$	111,015		$	92,473

4